NovaBay Pharmaceuticals Bilan de santé
Santé financière contrôle des critères 2/6
NovaBay Pharmaceuticals has a total shareholder equity of $-617.0K and total debt of $696.0K, which brings its debt-to-equity ratio to -112.8%. Its total assets and total liabilities are $3.9M and $4.5M respectively.
Informations clés
-112.8%
Ratio d'endettement
US$696.00k
Dette
| Ratio de couverture des intérêts | n/a |
| Argent liquide | US$751.00k |
| Fonds propres | -US$617.00k |
| Total du passif | US$4.54m |
| Total des actifs | US$3.93m |
Mises à jour récentes de la santé financière
Analyse de la situation financière
Passif à court terme: NBY has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Passif à long terme: NBY has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Historique et analyse du ratio d'endettement
Niveau d'endettement: NBY has negative shareholder equity, which is a more serious situation than a high debt level.
Réduire la dette: NBY's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Bilan
Analyse des pistes de trésorerie
Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.
Piste de trésorerie stable: NBY has sufficient cash runway for 3 months based on last reported free cash flow, but has since raised additional capital.
Prévisions de trésorerie: NBY is forecast to have sufficient cash runway for 2 months based on free cash flow estimates, but has since raised additional capital.